熱門資訊> 正文
随着2026财年收入指引提高，Twist Bioscience股价上涨
2026-02-02 21:54
- Despite reporting mixed fiscal 2026 Q1 financial results, Twist Bioscience (TWST) is up ~7% in premarket trading Monday after boosting its revenue guidance for the year.
- The DNA-based life sciences tools company now sees FY26 revenue of $435M-$445M, up from $425M-$435M prior. Consensus is $431.67M.
- The company also projects FY26 Q2 revenue of $107M-$108M. Consensus is $104.36M.
- In Q1, Twist beat on the bottom line but missed on the top line. The quarterly non-GAAP EPS loss of -$0.50 improved from -$0.53 in the year-ago period.
- Twist ended 2025 with $198M in cash, cash equivalents, and short-term investments, compared to $232.4M on Sept. 30, 2025.
More on Twist Bioscience
- 44th Annual J.P. Morgan Healthcare Conference
- Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Twist Bioscience Is Bent, Not Broken: Near-Term Strain, Long-Term Strength
- Twist Bioscience GAAP EPS of -$0.50 misses by $0.07, revenue of $103.7M beats by $1.66M
- Twist Bioscience Q1 2026 Earnings Preview
推薦文章
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
一周IPO | 賺錢效應持續火熱！年內24只上市新股「0」破發；「圖模融合第一股」海致科技首日飆漲逾242%
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
